echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Pharmaceutical stocks trend polarizing institutions looking for the wrong target

    Pharmaceutical stocks trend polarizing institutions looking for the wrong target

    • Last Update: 2021-02-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Affected by the vaccine event, A-share pharmaceutical bio-sector has become the focus of recent market attention. After Monday's sharp decline, the pharmaceutical and biological sector rebounded yesterday, with nearly 90 percent of stocks in the sector recording gains.
    tuesday, the pharmaceutical and biological sector was in a good place.
    opening stage, Shenwan Pharmaceutical Bio-Industry Index continued the downward trend, opening nearly 1%, most of the industry's inertia low open, Zhifei Bio and other vaccine stocks opened down.
    10:00 a.m., Hengrui Pharmaceuticals, Yunnan White Pharmaceuticals, Kangmei Pharmaceuticals and other pharmaceutical sector weighting stocks took the lead in the rebound, driving the pharmaceutical industry index quickly turned red.
    10:30, the demonstration effect of the weight stocks spread to most of the industry, Steyr, Asia Pacific Pharmaceuticals and many other small market value varieties have closed the rise and stop. Vaccine stocks zhifei bio-release opened and stopped, the stock price in less than 15 minutes after the fall opened red.
    close yesterday, the Shenwan Pharmaceutical Bio-Industry Index was up 1.43 per cent, with 249 of the industry's 287 stocks recording gains, or nearly 90 per cent.
    the industry rebounded yesterday, but Changsheng Bio, Kantai Bio two vaccine stocks are still a big single dead nailed to the board. Among them, Changsheng Bio's share price fell for the 7th consecutive day, falling and stopping the board to close the order of 735,500 hands, the whole day traded 4678 hands, the transaction amount of 5.4966 million yuan.
    yesterday's rally, the recent correction in the pharmaceutical and biological sector has been evident since the first fall on July 16th. Among the many sub-sectors, the bio-products sector, which includes vaccines, led the decline sharply, falling 10.50 per cent during this period. The medical services sector was close behind, falling 7.12 per cent. The pharmaceutical business sector was the most resistant, falling 1.73 per cent.
    the overall downward adjustment of individual stocks in the industry, a number of brokerages began to pay attention to some of the mis-killed varieties of investment opportunities.
    Ping An Securities said that considering the continued fermentation of vaccine events, market funds in the short term allocation of the pharmaceutical industry is not strong momentum. However, the local impact is greater than the overall, if the market appears on the pharmaceutical industry no difference, irrational killing, then for long-term value investors will bring a good buying opportunity to continue to recommend the market style killed by the undervaluation sub-sector leader.
    Guangda Securities suggested to pay attention to the pharmaceutical circulation sector, that the pharmaceutical circulation sector is currently in the low valuation, circulation enterprises are more sensitive to interest rates and credit delivery, and the current capital pressure has eased. In addition, the impact of the two-vote system gradually eliminated, some enterprises half-yearly results began to show month-on-month improvement.
    China Galaxy Securities recommended attention to the OTC sector, the OTC industry as a whole is currently in the process of concentration promotion, brand barriers and sales channel barriers are rising, in the early business reform, two-vote system and other policies under the influence of small enterprises to accelerate withdrawal. At the same time, the upgrading of pharmaceutical consumption, pharmaceutical consumers' brand awareness, but also to have brand advantages of pharmaceutical leading enterprises. (Shanghai Securities News)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.